search

Active clinical trials for "Carcinoma, Islet Cell"

Results 21-30 of 37

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

GastrinomaGlucagonoma19 more

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

Completed28 enrollment criteria

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

GastrinomaGlucagonoma7 more

This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Completed52 enrollment criteria

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid TumorPulmonary Carcinoid Tumor2 more

This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

Completed31 enrollment criteria

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid...

Extensive Stage Small Cell Lung CancerHereditary Paraganglioma46 more

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

Completed28 enrollment criteria

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor...

Pancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G21 more

This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.

Completed64 enrollment criteria

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine...

Pancreatic Alpha Cell CarcinomaPancreatic Beta Islet Cell Carcinoma3 more

This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with advanced pancreatic neuroendocrine tumors (PNET) that cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be an effective treatment for patients with PNET.

Completed61 enrollment criteria

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib...

Metastatic Breast CancerAdvanced Breast Cancer10 more

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

Completed2 enrollment criteria

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Gastrin-Producing Neuroendocrine TumorLung Carcinoid Tumor9 more

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Completed45 enrollment criteria

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine...

GastrinomaGlucagonoma7 more

The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.

Completed55 enrollment criteria

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive...

Islet Cell CarcinomaNeuroendocrine Carcinoma2 more

The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment.

Completed18 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs